Fulgent Genetics, Inc. reiterated earnings guidance for the year 2024. For the full year 2024, Fulgent continues to expect Core Revenue of approximately $280 million and GAAP loss of approximately $2.25 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.35 USD | -0.33% | -5.41% | -26.15% |
05-03 | Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024 | |
05-03 | Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.15% | 639M | |
-20.81% | 7.83B | |
+67.01% | 4.29B | |
-0.93% | 2.58B | |
-8.93% | 2.48B | |
-38.69% | 2.46B | |
-10.75% | 1.84B | |
-19.84% | 1.53B | |
-40.24% | 1.22B | |
+16.56% | 1.2B |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024